Umang Vohra, the long-serving MD and Global CEO of Cipla, is expected to step down at the end of the fiscal year in March 2026, as per Live Mint. His tenure since 2016 has seen Cipla rise in domestic and international markets. Here's a look at his educational background and professional journey.
Umang Vohra holds a degree in engineering from MS Ramaiah Institute of Technology, Bangalore. He later completed his MBA in marketing and finance from TAPMI (T A Pai Management Institute), establishing firm academic credentials that have supported his leadership in global pharmaceutical firms. Vohra joined Cipla in October 2015 as Global CFO, moving quickly to the role of COO, and then MD & Global CEO by September 1, 2016. His current tenure is set to end on March 31, 2026.
Under Vohra's leadership, Cipla achieved strong operational improvements, including better profitability and expanding margins. He introduced agile business models, strengthened digital and data-driven decision-making, and led transformation in global markets. His persistent focus has been on innovation and making a meaningful impact on patients’ health globally.
Before his time at Cipla, Vohra built his career in reputable companies. He worked at Eicher Motors and PepsiCo, gaining multifaceted experience early on. He later held leadership roles at Dr. Reddy’s Laboratories, where he led the North America business. With close to 20 years of experience across India and the US, Vohra developed a 360-degree understanding of the pharma value chain.
Read More: Kaynes Technology CEO Rajesh Sharma Resigns Effective October 31, 2025; Share Price Plunges!
While no official statement has been made yet, reports suggest Cipla is preparing for leadership change. Achin Gupta, current Global COO and former CEO of the One India business, has emerged as the probable successor. Gupta is credited with expanding Cipla’s presence in Tier 2 to 6 towns and driving substantial revenue growth.
Umang Vohra’s upcoming exit marks the end of a significant era at Cipla. With a strong academic base and nearly 2 decades of industry expertise, his leadership has helped shape Cipla into a stronger global brand. The transition signals a new phase for the pharmaceutical major, possibly under a new leadership direction.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Oct 9, 2025, 12:50 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates